Elutia Inc

ELUT • Biotechnology

$0.82

▼ -0.02 (-2.24%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$36.32M

Growth

-30.2%

Cash Flow

0/5

Trend

Negative

Evidence

Reasonable earnings multiple · 0.54Manageable debt level · 0.27Healthy liquidity · 2.22Negative growth trend

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:13 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.82

Change-2.24%

Shares Out44.22M

Market Cap$36.32M

Enterprise Value$20.80M

52W Range0.50 - 2.50

Beta0.88

P/E0.70

P/S2.99

P/B2.31

P/FCF-0.80

EV/Sales1.71

Price$0.82

Change-2.24%

Shares Out44.22M

Market Cap$36.32M

Enterprise Value$20.80M

52W Range0.50 - 2.50

Beta0.88

P/E0.70

P/S2.99

P/B2.31

P/FCF-0.80

EV/Sales1.71

EV/EBITDA-1.16

EV/FCF-0.46

Earnings Yield142.66%

FCF Yield-125.22%

Dividend Yield0.00%

Gross Margin53.66%

Oper. Margin-149.78%

Profit Margin4.34%

Debt/Eq0.27

Current Ratio2.22

Quick Ratio2.12

Revenue 5Y-30.15%

Target$8.88

Target Upside981.34%

Target Median$10.00

Target Range5.00 - 10.50

Volume66.98K

Avg Volume96.11K

EPS Surprise-0.02

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

43/100

Financial Strength

Debt, cash, stability

95/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

92/100

Why this score▼

Reasonable earnings multiple · 0.54Manageable debt level · 0.27Healthy liquidity · 2.22Negative growth trend

Analyst view

Analyst sentiment and price target

ELUT

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Price Target

2026-08-16

Low

$5.00

Mean

$8.88

Median

$10.00

High

$10.50

Company Overview

IPO: 10/7/2020

Industry: Biotechnology

P/B i: 2.31

Debt / Equity i: 0.27

Operating Margin: -149.78%

Net Margin: 4.34%

ROE i: -

ROIC: -

Financial Health

Score19 / 20

Debt / Equity: 0.27

Current Ratio: 2.22

Quick Ratio: 2.12

Status: Strong

Insider Transactions

Recent executive and insider activity

Mills C Randal

Transaction: 06/21/2026

SELL

Change

-22,473

Price

Not reported

Filing

06/22/2026

Type

SELL

Mills C Randal

Transaction: 06/21/2026

SELL

Change

-8,064

Price

$1.06

Filing

06/22/2026

Type

SELL

Makes Brigid

Transaction: 06/11/2026

BUY

Change

+106,393

Price

$0.96

Filing

06/15/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Mills C Randal	SELL	-22,473	Not reported	06/21/2026	06/22/2026
Mills C Randal	SELL	-8,064	$1.06	06/21/2026	06/22/2026
Makes Brigid	BUY	+106,393	$0.96	06/11/2026	06/15/2026
NEELS GUIDO J	BUY	+106,393	$0.96	06/11/2026	06/15/2026
Colpman David	BUY	+106,393	$0.96	06/11/2026	06/15/2026
RAKIN KEVIN	BUY	+159,590	$0.96	06/11/2026	06/15/2026
Mills C Randal	SELL	-27,083	Not reported	06/10/2026	06/12/2026
Mills C Randal	SELL	-9,718	$1.04	06/10/2026	06/12/2026
Ferguson Matthew	SELL	-12,500	Not reported	06/10/2026	06/12/2026
Ferguson Matthew	SELL	-4,485	$1.04	06/10/2026	06/12/2026
Williams Michelle LeRoux	SELL	-12,500	Not reported	06/10/2026	06/12/2026
Williams Michelle LeRoux	SELL	-4,269	$1.04	06/10/2026	06/12/2026
RAKIN KEVIN	SELL	-70,000	Not reported	06/01/2026	06/02/2026
NEELS GUIDO J	SELL	-6,250	Not reported	12/10/2025	04/14/2026
NEELS GUIDO J	BUY	+6,250	Not reported	12/10/2025	04/14/2026
Ferguson Matthew	SELL	-12,500	Not reported	03/10/2026	03/12/2026
Mills C Randal	SELL	-27,084	Not reported	03/10/2026	03/12/2026
Mills C Randal	SELL	-11,100	$1.09	03/10/2026	03/12/2026
Ferguson Matthew	SELL	-5,123	$1.09	03/10/2026	03/12/2026
Williams Michelle LeRoux	SELL	-12,500	Not reported	03/10/2026	03/12/2026

About the Company

Elutia Inc

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Source - link

Peers

ANVS BCAB CALC CELU LTRN MAIA PYPD RNXT RVPH TVRD

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. Michelle Williams, Chief Scientific Officer, will participate in two upcoming investor conferences.

GlobeNewsWire

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (Nasdaq: ELUT).

GlobeNewsWire

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months Divestiture further concentrates Elutia's attention and resources on the development and commercialization of NXT-41x NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market NXT-41x clearance expected in the first half of 2027 GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it completed the sale of its SimpliDerm® human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million.

GlobeNewsWire

Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript

Seeking Alpha

Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The demand is strong: 96% of surgeons surveyed are interested in adopting NXT-41x; 92% responded they would champion it at their hospital value analysis committee On track: NXT-41 FDA clearance decision expected in 4Q 2026; NXT-41x FDA clearance decision expected in 1H 2027 GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and announced financial results for the second quarter ended June 30, 2026.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-14	-0.15	-0.17	-0.02
2026-03-11	-0.14	-0.14	0
2025-11-06	-0.155	-0.01	0.145
2025-08-14	-0.17	-0.26	-0.09
2025-05-08	-0.2	-0.21	-0.01
2025-03-06	-0.25	-0.26	-0.01
2024-11-14	-0.44	-0.33	0.11
2024-08-07	-0.33	-1.14	-0.81
2024-05-09	-0.41	-0.75	-0.34
2024-03-07	-0.28	-0.66	-0.38
2023-11-13	-0.53	-0.5	0.03
2023-08-14	-0.29	-0.65	-0.36